Zhitong Finance App News, Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd. (“Huabo Kaisheng”), a wholly-owned subsidiary of the company, recently received the “Notice of Acceptance” of the application for registration and marketing of drugs produced domestically by methimazole tablets issued by the State Drug Administration.

According to the announcement, methimazole is an imidazole antithyroid drug. By inhibiting the activity of thyroid peroxidase (TPO), a key enzyme in the thyroid gland, it blocks the absorption of the coupling of iodide and tyrosine in the thyroid gland, and hinders the synthesis of thyroid T4 and triiodothyronine T3. Methimazole tablets are a commonly used anti-thyroid drug. They are mainly used to treat hyperthyroidism, especially patients with mild hyperthyroidism and mild to moderate thyroid enlargement, and can also be used to treat recurrence after thyroid surgery. In addition, methimazole tablets can also be used to prepare medication for patients with hyperthyroidism before treatment with radioactive iodine, and can be used to prevent thyrotoxic crises in patients after treatment.